Observational studyClinical immunology (Orlando, Fla.)2021

Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.

Miguel García-Grimshaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.